The firm expects to report topline data from the trial near the end of 2025 and may submit the data as part of a regulatory application in China.

In an earlier study, patients with biomarker-positive high-grade glioma lived longer after treatment with DB107 than biomarker-negative patients.

PCRX-201 became part of Pacira's portfolio in 2021, but was originally developed at Baylor and then by GQ Bio Therapeutics, ...

Researchers will use the funds to identify molecular signatures linked to different disease subtypes and test drugs on brain organoids.

After a promising feasibility study showing the potential of its natural language processing models, MSK has ambitions to use them in patient care.

Ataraxis AI will use the new funding to bring to market its first offering, Ataraxis Breast, an AI-native prognostic/predictive platform for breast cancer.

Researchers are testing whether the Clarity ctDNA test can reliably identify patients who do just as well long term with less chemotherapy.

Troculeucel is an immunotherapeutic, in which a patient's autologous natural killer cells are expanded ex vivo. It is designed to reduce or prevent chronic neuroinflammation in patients who have ...

In the randomized, sham-controlled ARTEMIS study, patients will receive either a dose of ixo-vec or a standard care regimen of anti-VEGF Eylea.

The presence of primary resistance and KRAS G12C co-mutations may explain limited single-agent efficacy of marketed KRAS inhibitors, a recent study suggests.

Patients with PD-L1-positive tumors lived more than seven months longer on Tevimbra added to chemotherapy compared to just chemo.

In a recent trial, researchers found that Xpovio plus chemo had activity in NSCLC patients with KRAS mutations other than ...